Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis

Fig. 1

Ancillary study design from the APPRAISE trial. Of the 104 patients with rheumatoid arthritis (RA) enrolled in the APPRAISE trial, 68 were included in our ancillary study after discarding patients with missing data or poor-quality RNA samples. Among these 68 patients with RA, two subsets were designated, one for identification and one for validation. The first step of this ancillary study was to identify clinical parameters to predict abatacept (ABA)/methotrexate (MTX) response. The second step was to identify a gene combination able to predict ABA/MTX response. Subset 1, comprising 36 patients with RA, was used to identify clinical parameters or gene combinations to predict drug response. Subset 2, comprising 32 patients with RA, was used to validate these clinical parameters or gene combinations. qRT-PCR quantitative reverse-transcription PCR

Back to article page